



Innovative back microsurgery

Press release

VEXIM Presents its Financial Agenda for 2015

Toulouse, December 19, 2014 - VEXIM (FR0011072602 - ALVXM / PEA-PME eligible), a medical device company specializing in the minimally-invasive treatment of vertebral fractures, today announced its preliminary financial agenda for 2015.

ANNOUNCEMENT	DATE *
2014 Full-Year Sales	Monday, January 26, 2015
2014 Full-Year Results	Tuesday, March 24, 2015
Q1 2015 Sales	Thursday, April 16, 2015
Annual General Meeting	Tuesday, May 19, 2015
2015 Half-Year Sales	Monday, July 20, 2015
2015 Half-Year Results	Wednesday, September 30, 2015
Q3 2015 Sales	Tuesday, November 3, 2015

Financial year ended December 31

** Subject to modification. Press releases are distributed after the financial markets closure.*

About VEXIM, the innovative back microsurgery specialist

Based in Balma, near Toulouse (France), VEXIM is a medical device company created in 2006. The Company has specialized in the creation and marketing of mini-invasive solutions for treating traumatic spinal pathologies. Benefitting from the financial support of its longstanding shareholders, Truffle Capital and Banexi Venture, and from Bpifrance public subsidies, VEXIM has designed and developed the SpineJack®, a unique implant capable of repairing a fractured vertebra and restoring the balance of the spinal column. The Company currently has 59 staff. It has its own sales teams in France, Germany, Italy, Spain, Switzerland and the United Kingdom, as well as distributors notably in Argentina, India, Taiwan, Belgium, South Africa, Colombia, Panama, Venezuela, Chile, and Ecuador and in the following countries where the product is currently being registered: Mexico, Brazil and Peru. VEXIM has been listed on Alternext Paris since May 2012.

For further information, please go to www.vexim.com

SpineJack^{®1} implant for treating Vertebral Compression Fractures

An important advantage of SpineJack[®] lies in its ability to restore a fractured vertebra to its original shape, restore the spinal column's optimal anatomy and thus remove pain and enable the patient to recover their functional capabilities. Specialized instruments and guided by X-ray allow the implants into the vertebra to be carried out by mini-invasive surgery in approximately 30 minutes enabling the patient to be discharged shortly after surgery. The SpineJack[®] range consists of three titanium implants with three different diameters, thus covering 95% of vertebral compression fractures and all patient morphologies. SpineJack[®] technology benefits from the support of international scientific experts in the field of spine surgery and worldwide patent protection until 2029. SpineJack[®] is an investigational device in the United States and is not available for U.S. sale.

Contacts

VEXIM

Vincent Gardès

CEO

Tel: +33 5 61 48 48 38

shareholders@vexim.com

NewCap

Investor Relations /
Strategic

Communications

Dusan Oresansky /

Emmanuel Huynh

Tel: +33 1 44 71 94 92

vexim@newcap.fr

Alize RP

Press Relations

Caroline Carmagnol /

Sophie Colin

vexim@alizerp.com

Tel: +33 1 44 54 36 66 /

+33 6 64 18 99 59

LifeSci Advisors LLC

Investor Relations

Michael Wood

www.lifesciadvisors.com

+1 646 597 6983



- **Name:** VEXIM
- **ISIN code:** FR0011072602
- **Ticker:** ALVXM
- **Member of the EnterNext© PEA-PME 150 index**



¹ This medical device is a regulated health product that, with regard to these regulations, bears the CE mark. Please refer to the Instructions for Use.